These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 34294105)

  • 1. N6-Methyladenosine RNA modification in cerebrospinal fluid as a novel potential diagnostic biomarker for progressive multiple sclerosis.
    Ye F; Wang T; Wu X; Liang J; Li J; Sheng W
    J Transl Med; 2021 Jul; 19(1):316. PubMed ID: 34294105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid sulfatide isoforms lack diagnostic utility in separating progressive from relapsing-remitting multiple sclerosis.
    Novakova L; Henricsson M; Björnson E; Axelsson M; Borén J; Rosenstein I; Lycke J; Cardell SL; Blomqvist M
    Mult Scler Relat Disord; 2023 Jun; 74():104705. PubMed ID: 37060853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Metabolite Biomarkers of Multiple Sclerosis from Multiple Biofluids.
    Bhinderwala F; Roth HE; Filipi M; Jack S; Powers R
    ACS Chem Neurosci; 2024 Mar; 15(6):1110-1124. PubMed ID: 38420772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
    Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
    PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid foot-tapping but not hand-tapping ability is different between relapsing-remitting and progressive multiple sclerosis.
    Sato S; Lim J; Miehm JD; Buonaccorsi J; Rajala C; Khalighinejad F; Ionete C; Kent JA; van Emmerik REA
    Mult Scler Relat Disord; 2020 Jun; 41():102031. PubMed ID: 32172213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Novel Biomarkers for Diagnosing and Predicting the Progression of Multiple Sclerosis Using TMT-Based Quantitative Proteomics.
    Shi Y; Ding Y; Li G; Wang L; Osman RA; Sun J; Qian L; Zheng G; Zhang G
    Front Immunol; 2021; 12():700031. PubMed ID: 34489947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioinformatics identification and experimental validation of m6A-related diagnostic biomarkers in the subtype classification of blood monocytes from postmenopausal osteoporosis patients.
    Zhang P; Chen H; Xie B; Zhao W; Shang Q; He J; Shen G; Yu X; Zhang Z; Zhu G; Chen G; Yu F; Liang D; Tang J; Cui J; Liu Z; Ren H; Jiang X
    Front Endocrinol (Lausanne); 2023; 14():990078. PubMed ID: 36967763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive MS from relapsing-remitting MS.
    Novakova L; Singh AK; Axelsson M; Ståhlman M; Adiels M; Malmeström C; Zetterberg H; Borén J; Lycke J; Cardell SL; Blomqvist M
    J Neurochem; 2018 Aug; 146(3):322-332. PubMed ID: 29676479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of m6A RNA Methylation-Related Genes in Liver Hepatocellular Carcinoma and Their Correlation with Survival.
    Li Y; Qi D; Zhu B; Ye X
    Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33540684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the N6-methyladenosine regulatory factor in reducing the risk of cardiovascular disease: subtype diagnosis following aerobic exercise-assisted weight loss.
    Hao X; Li Y; Huang G; Zeng Y
    Am J Transl Res; 2022; 14(8):5363-5378. PubMed ID: 36105062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of the m6A-related molecular patterns and diagnostic biomarkers in osteoporosis.
    Bai Q; Shi M; Sun X; Lou Q; Peng H; Qu Z; Fan J; Dai L
    Front Endocrinol (Lausanne); 2022; 13():957742. PubMed ID: 36034449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N6-methyladenosine regulator-mediated methylation modification patterns and immune infiltration characterization in Polycystic Ovary Syndrome (PCOS).
    Zhou S; Hua R; Quan S
    J Ovarian Res; 2023 Apr; 16(1):73. PubMed ID: 37046273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study.
    Zanghì A; Manuti V; Serviddio G; D'Amico E; Avolio C
    Front Immunol; 2023; 14():1226130. PubMed ID: 37711630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of m6A-regulated genes and subtype classification in lupus nephritis.
    Li D; Li Y; Zhu K; Yuan Y; He Z; Sun Q; Jin M
    BMC Nephrol; 2024 Apr; 25(1):119. PubMed ID: 38570749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization of m6A RNA methylation regulators with features of immune dysregulation in IgA nephropathy.
    Wang Y; Sun N; He R; Wang Z; Jin J; Gao T; Qu J
    Clin Exp Med; 2024 May; 24(1):92. PubMed ID: 38693353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. m6A Regulator-Mediated Methylation Modification Patterns and Characteristics in COVID-19 Patients.
    Qing X; Chen Q; Wang K
    Front Public Health; 2022; 10():914193. PubMed ID: 35655464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment.
    Du Y; Ma Y; Zhu Q; Liu T; Jiao Y; Yuan P; Wang X
    Front Pharmacol; 2021; 12():707930. PubMed ID: 34248650
    [No Abstract]   [Full Text] [Related]  

  • 18. Comprehensive Analysis of N6-Methyladenosine Regulators in the Subcluster Classification and Drug Candidates Prediction of Severe Obstructive Sleep Apnea.
    Li N; Gao Z; Shen J; Liu Y; Wu K; Yang J; Wang S; Zhang X; Zhu Y; Zhu J; Guan J; Liu F; Yin S
    Front Genet; 2022; 13():862972. PubMed ID: 35559050
    [No Abstract]   [Full Text] [Related]  

  • 19. Construction of m6A-Related Gene Prediction Model and Subtype Analysis in Non-Obstructive Azoospermia Based on Bioinformatics.
    Li G; Che K; Wu J; Yang B
    Am J Reprod Immunol; 2024 Jul; 92(1):e13892. PubMed ID: 38958252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis.
    Maier S; Barcutean L; Andone S; Manu D; Sarmasan E; Bajko Z; Balasa R
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.